BMRN vs. BNTX: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BMRN and BNTX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
BMRN is a standard domestic listing, while BNTX trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | BMRN | BNTX |
|---|---|---|
| Company Name | BioMarin Pharmaceutical Inc. | BioNTech SE |
| Country | United States | Germany |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Biotechnology |
| Market Capitalization | 10.50 billion USD | 24.64 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | July 26, 1999 | October 10, 2019 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of BMRN and BNTX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BMRN | BNTX |
|---|---|---|
| 5-Day Price Return | 3.91% | -1.88% |
| 13-Week Price Return | -4.88% | -9.19% |
| 26-Week Price Return | -8.45% | 9.09% |
| 52-Week Price Return | -17.90% | -7.53% |
| Month-to-Date Return | 2.17% | -0.79% |
| Year-to-Date Return | -16.74% | -9.53% |
| 10-Day Avg. Volume | 2.36M | 0.98M |
| 3-Month Avg. Volume | 2.29M | 0.84M |
| 3-Month Volatility | 26.60% | 40.02% |
| Beta | 0.27 | 1.42 |
Profitability
Return on Equity (TTM)
BMRN
8.84%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
BMRN’s Return on Equity of 8.84% is on par with the norm for the Biotechnology industry, indicating its profitability relative to shareholder equity is typical for the sector.
BNTX
-3.04%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
BNTX has a negative Return on Equity of -3.04%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
BMRN
16.82%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
BMRN’s Net Profit Margin of 16.82% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
BNTX
8.52%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
BNTX’s Net Profit Margin of 8.52% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
BMRN
19.89%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
BMRN’s Operating Profit Margin of 19.89% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
BNTX
3.75%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
BNTX’s Operating Profit Margin of 3.75% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | BMRN | BNTX |
|---|---|---|
| Return on Equity (TTM) | 8.84% | -3.04% |
| Return on Assets (TTM) | 7.13% | -2.64% |
| Net Profit Margin (TTM) | 16.82% | 8.52% |
| Operating Profit Margin (TTM) | 19.89% | 3.75% |
| Gross Profit Margin (TTM) | 81.32% | 86.80% |
Financial Strength
Current Ratio (MRQ)
BMRN
4.83
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
BMRN’s Current Ratio of 4.83 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
BNTX
7.12
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
BNTX’s Current Ratio of 7.12 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
BMRN
0.10
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
BMRN’s Debt-to-Equity Ratio of 0.10 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
BNTX
0.01
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
BNTX’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
BMRN
-21.18
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
BMRN has a negative Interest Coverage Ratio of -21.18. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
BNTX
-1.43
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
BNTX has a negative Interest Coverage Ratio of -1.43. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | BMRN | BNTX |
|---|---|---|
| Current Ratio (MRQ) | 4.83 | 7.12 |
| Quick Ratio (MRQ) | 3.10 | 7.02 |
| Debt-to-Equity Ratio (MRQ) | 0.10 | 0.01 |
| Interest Coverage Ratio (TTM) | -21.18 | -1.43 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BMRN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
BNTX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BNTX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
BMRN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
BNTX
17.60%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 17.60%, BNTX’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
Dividend at a Glance
| Symbol | BMRN | BNTX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 17.60% |
Valuation
Price-to-Earnings Ratio (TTM)
BMRN
20.17
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
BMRN’s P/E Ratio of 20.17 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
BNTX
--
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
P/E Ratio data for BNTX is currently unavailable.
Price-to-Sales Ratio (TTM)
BMRN
3.39
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
In the lower quartile for the Biotechnology industry, BMRN’s P/S Ratio of 3.39 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
BNTX
7.89
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
BNTX’s P/S Ratio of 7.89 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
BMRN
1.72
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
BMRN’s P/B Ratio of 1.72 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
BNTX
1.11
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
BNTX’s P/B Ratio of 1.11 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | BMRN | BNTX |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 20.17 | -- |
| Price-to-Sales Ratio (TTM) | 3.39 | 7.89 |
| Price-to-Book Ratio (MRQ) | 1.72 | 1.11 |
| Price-to-Free Cash Flow Ratio (TTM) | 12.71 | 24.88 |